August 2010
Worldwide Biotech;Aug2010, Vol. 22 Issue 8, p5
Trade Publication
The article offers information on a milestone payment of 15 million U.S. dollars made by Bayer to GW Pharmaceuticals. The milestone was paid in line with the British government's approval of the GW Pharmaceuticals' Sativex oromucosal spray tincture for patients with spasticity from multiple sclerosis (MS). Sales forecasts for the Sativex are projected at 180 million U.S. dollars in Europe and Canada.


Related Articles

  • Almirall and GW Pharmaceuticals receive approval of MS drug in Germany.  // PharmaWatch: CNS;Jul2011, Vol. 10 Issue 7, p7 

    The article reports on the regulatory approval issued for Sativex and cannabiol oromucosal spray as an add-on therapy for the treatment of moderate to severe spasticity resulting from multiple sclerosis (MS) developed by GW Pharmaceuticals PLC and marketed by Almirall SA in Germany. It notes...

  • GW Pharmaceuticals: high expectations for cannabis drug.  // PharmaWatch: CNS;June 2004, Vol. 3 Issue 6, p5 

    Reports on GW Pharmaceuticals PLC and Bayer HealthCare LLC's submission of a New Drug Submission for Sativex, a cannabis-based medicine for the symptomatic treatment of multiple sclerosis and neuropathic pain, to Health Canada. Drug delivery systems; Concerns of GW Pharmaceuticals over the...

  • GW Announces UK Launch of World's First Prescription Cannabis Medicine.  // Operating Theatre Journal;Jul2010, Issue 238, p8 

    The article reports on the announcement of GW Pharmaceuticals PLC regarding the Great Britain launch of Sativex(R), the first prescription cannabis-based medicine for spasticity due to multiple sclerosis (MS).

  • Positive U.S. Phase IIb Trial for GW's Sativex.  // Bioworld Week;3/29/2010, Vol. 18 Issue 13, p4 

    The article reports on GW Pharmaceuticals PLC which seeks U.S. approval for preliminary Phase IIb trial of its cannabis-based medicine Sativex in treating pain for patients with advanced cancer.

  • Fresh Study Provides Positive Data On GW's Sativex For Pain. Moran, Nuala // BioWorld International;10/24/2007, Vol. 12 Issue 43, p1 

    The article reports on a study which found cannabis-based medicine Sativex effective in treating central neuropathic pain caused by multiple sclerosis. The randomized controlled trial involved 66 patients. Sativex is a sub lingual spray developed by GW Pharmaceuticals PLC. Company R&D director...

  • EUROPE TO MARKET POT FOR PAIN. Houlton, Sarah // Pharmaceutical Executive;Jul2003, Vol. 23 Issue 7, p19 

    Reports that GW Pharmaceuticals has granted exclusive rights to Bayer AG to market Sativex, a cannabis-base medicines in Great Britain. Effectiveness of Sativex in the treatment of multiple sclerosis; Reduction of neuropathic pain.

  • WHAT TO TELL YOUR PATIENTS.  // GP: General Practitioner;11/18/2002, p55 

    Focuses on the statement given by GW Pharmaceuticals PLC regarding the use of cannabis-based product for the treatment of multiple sclerosis (MS). Disadvantages of using cannabis for the treatment of MS.

  • GW Shares Take A Blow With Delay On Sativex. Moran, Nuala // BioWorld International;7/25/2007, Vol. 12 Issue 30, p1 

    The article reports on the decline in shares of GW Pharmaceuticals after its forced withdrawal to submit Sativex as treatment for spasticity in multiple sclerosis. Chief executive officer Justin Gover explains the action did not involve issues on quality or safety. Mike Barnes, president of the...

  • GW Pharma Hits the Mark in Phase III Sativex MS Trial. Moran, Nuala // BioWorld International;3/18/2009, Vol. 14 Issue 11, p1 

    The article reports on the announcement by GW Pharmaceuticals plc of statistically significant results in a Phase III study of its cannabis-based drug Sativex in the treatment of spasticity due to multiple sclerosis. The company has finally been allowed to refile the dossier in Great Britain six...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics